$338 Mln
$-29 Mln
--
As on 29-Sep-2023 16:00 EDT
$0.01
•
0.34%
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Humacyte (HUMA)
| 38.86 | -26.38 | -3.30 | -17.46 | -- | -- | -- |
|
S&P BSE Sensex
| 8.20 | 1.28 | 2.99 | 16.31 | 20.12 | 12.69 | 12.81 |
|
S&P Small-Cap 600#
| -0.54 | -5.85 | -5.24 | 7.40 | 10.50 | 1.63 | 6.62 |
|
2022
|
|
|---|---|
|
Humacyte (HUMA)
| -70.90 |
|
S&P Small-Cap 600
| -17.42 |
|
S&P BSE Sensex
| 4.44 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
The total asset value of Humacyte Inc. (HUMA) stood at $ 207 Mln as on 31-Mar-23
The share price of Humacyte Inc. (HUMA) is $2.930000 (NASDAQ) as of 29-Sep-2023 16:00 EDT. Humacyte Inc. (HUMA) has given a return of -17.46% in the last 1 years.
Humacyte Inc. (HUMA) has a market capitalisation of $ 338 Mln as on 11-Aug-2023. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Humacyte Inc. (HUMA) is 2.40 times as on 11-Aug-2023, a -0.06% premium to its peers’ median range of 2.54 times.
Since, TTM earnings of Humacyte Inc. (HUMA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Humacyte Inc. (HUMA) and enter the required number of quantities and click on buy to purchase the shares of Humacyte Inc. (HUMA).
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
The CEO & director of Dr. Laura E. Niklason M.D., Ph.D.. is Humacyte Inc. (HUMA), and CFO & Sr. VP is Mr. Dale A. Sander.
The promoters of Humacyte Inc. (HUMA) have pledged 0% of the total equity as on Mar-23.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
498
|
|
|
497
|
|
|
392
|
|
|
383
|
| Humacyte Inc. (HUMA) | Ratios |
|---|---|
|
Return on equity(%)
|
18.52
|
|
Return on capital employed(%)
|
--
|
|
Debt-to-equity ratio
|
0.2
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Humacyte Inc. (HUMA) was $-29 Mln.
$338.14 Mln
$0.00 Mln
$-29.10 Mln
$131.68 Mln
$47.52 Mln
High
$1.96 - 5.60
103,408,000
NASDAQ: HUMA
Durham, NC
https://www.humacyte.com
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company... using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina. Read more
Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.
Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.
Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.
Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.
Unlimited access to advice from India's top experts
The most comprehensive analysis of funds and stocks in India
A holistic portfolio manager to help track all your investments easily
And much more, like guides, tools, webinars, videos and eBooks.
Share via Facebook 
Share via Twitter 
Share via LinkedIn 
Share this
